Trump Psychedelics Order

Trump signed an executive order to accelerate research on psychedelics including psilocybin, MDMA, and ibogaine, directing the FDA to expand clinical trials and "Right to Try" access for serious mental health conditions. Drug scheduling remains unchanged. Psychedelic stocks surged, with AtaiBeckley up ~25% Monday and gains across Compass Pathways, Definium Therapeutics, and Cybin.